Recombinant Cynomolgus Interleukin-17A/IL-17A (C-6His) | PKSQ050109

Recombinant Cynomolgus Interleukin-17A/IL-17A (C-6His) | PKSQ050109 | Gentaur US, UK & Europe Disrtribition

Synonyms: Interleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17

Active Protein: Active protein

Activity: Recombinant Cynomolgus Interleukin-17A is produced by our Mammalian expression system and the target gene encoding Gly24­Ala155 is expressed with a 6His tag at the C-terminus.

Protein Construction: Recombinant Cynomolgus Interleukin-17A is produced by our Mammalian expression system and the target gene encoding Gly24­Ala155 is expressed with a 6His tag at the C-terminus.

Fusion Tag: C-6His

Species: Cynomolgus

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 15.9 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

Research Area: N/A